100 completed, 19 terminated, 9 unknown, 5 recruiting. 43 Phase 2, 35 Phase 4, 32 Phase 1, 24 Phase 3, 8 Not applicable.
Follow this drug Literature Review of Maraviroc trials Research Report on Maraviroc
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies maraviroc (Selzentry, Celsentri) - Myositis | Phase 4 | Not yet recruiting | Chinese University of Hong Kong | 10 | 2026-09-01 | 2026-06-30 |
| Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals Maraviroc, Dolutegravir, Dendritic Cell Vaccine - Hiv, HIV I Infection | Phase 2 | Recruiting | Federal University of São Paulo | 70 | 2026-07-15 | 2026-08-19 |
| A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg, Placebo, Maraviroc - Long COVID | Phase 2 / Phase 3 | Not yet recruiting | HealthBio, Inc. | 252 | 2026-07-15 | 2026-06-18 |
| This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction Maraviroc, Placebo - Primary Graft Dysfunction, Lung Transplantation | Phase 2 | Recruiting | University of California, San Francisco | 120 | 2025-12-07 | 2026-01-20 |
| Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke Maraviroc, Mannitol - Ischemic Stroke, Stroke | Phase 2 | Recruiting | Emmanuel Carrera | 80 | 2025-07-14 | 2025-08-12 |
| Antiviral Clinical Trial for Long Covid-19 tenofovir disoproxil/emtricitabine, Selzentry, Placebo - Long Covid | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 90 | 2024-10-01 | 2026-03-13 |
| Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... RIC, GVHD prophylaxis, allo HCT - HIV, Hematologic Malignancies | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 265 | 2023-01-26 | 2026-10-16 |
| The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke Maraviroc, Exercise Program, Placebo - Stroke | Phase 2 | Unknown | University of Calgary | 120 | 2022-09-15 | 2024-07-09 |
| Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults Maraviroc + Currently used therapy, Curently used therapy for COVID-19 non-critical patients, Favipiravir + Currently used therapy - COVID-19 | Phase 2 | Terminated | Hospital General de México Dr. Eduardo Liceaga | 19 | 2021-07-13 | 2022-06-03 |
| Safety and Efficacy of Maraviroc in Post-stroke Cognitive Impairment Maraviroc - Post Stroke Cognitive Impairment | Phase 2 | Unknown | Tel-Aviv Sourasky Medical Center | 150 | 2021-05-01 | 2021-07-19 |
| Maraviroc in Patients With Moderate and Severe COVID-19 Maraviroc - COVID | Phase 1 | Completed | Rhode Island Hospital | 9 | 2020-10-01 | 2024-04-29 |
| Safety of Maraviroc for Post-stroke Depression Maraviroc 300 mg - Post-stroke Depression | Phase 2 | Completed | Tel-Aviv Sourasky Medical Center | 10 | 2020-08-04 | 2023-07-06 |
| Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19). Maraviroc 300 mg, Standard care therapy - COVID-19 | Phase 2 | Terminated | Hospital Universitario Infanta Leonor | 60 | 2020-06-26 | 2022-03-11 |
| Maraviroc to Augment Rehabilitation Outcomes After Stroke Maraviroc 300 mg, Rehabilitation therapy, Placebo 300 mg - Stroke | Phase 2 / Phase 3 | Terminated | University of California, Los Angeles | 2 | 2019-08-01 | 2021-08-03 |
| Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC Pembrolizumab, Maraviroc - Metastatic Colorectal Cancer, MSS | Phase 1 | Completed | University Hospital Heidelberg | 20 | 2018-04-01 | 2022-06-07 |
| The Role of Home Packs of HIV PEPSE in High Risk Individuals Maraviroc, Truvada - HIV-1-infection | Phase 4 | Completed | Guy's and St Thomas' NHS Foundation Trust | 139 | 2018-01-01 | 2021-07-22 |
| ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence Maraviroc Pill, Dolutegravir Pill, Truvada Pill - HIV/AIDS | Phase 4 | Completed | University of North Carolina, Chapel Hill | 36 | 2017-06-28 | 2019-11-22 |
| Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection Maraviroc - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 47 | 2017-06-05 | 2022-01-04 |
| Maraviroc Efficacy for Hepatitis C Maraviroc - Hepatitis C, Human Immunodeficiency Virus | Phase 4 | Completed | University of Maryland, Baltimore | 10 | 2017-06-01 | 2024-05-01 |
| Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X) emtricitabine, darunavir/cobicistat, maraviroc - Hiv, Neurocognitive Dysfunction | Phase 4 | Terminated | Giovanni Di Perri | 38 | 2017-05-15 | 2020-11-06 |
Showing 20 of 142. Sign in to see all of them.
HIV Infections (53) · Acquired Immunodeficiency Syndrome (36) · Diabetes Mellitus, Insulin-Dependent, 22 (3) · Graft vs Host Disease (3) · Stroke (3) · AIDS Dementia Complex (2) · COVID-19 (2) · Cardiovascular Diseases (2) · Colorectal Neoplasms (2) · Hematologic Neoplasms (2) · Infections (2) · Inflammation (2) · Post-Acute COVID-19 Syndrome (2) · Acute Lung Injury (1) · Anemia, Refractory, with Excess of Blasts (1)
ViiV Healthcare (32) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Kirby Institute (4) · St Stephens Aids Trust (4) · University of California, San Francisco (4) · ANRS, Emerging Infectious Diseases (3) · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal (3) · Imperial College London (3) · University of Maryland, Baltimore (3) · University of North Carolina, Chapel Hill (3) · Abramson Cancer Center at Penn Medicine (2) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (2) · Emory University (2) · Federal University of São Paulo (2) · Germans Trias i Pujol Hospital (2)
United States (67) · United Kingdom (21) · Spain (20) · Germany (18) · Canada (17) · Italy (13) · Puerto Rico (13) · France (12) · Australia (10) · Belgium (10) · Argentina (9) · Brazil (9) · Thailand (9) · Mexico (8) · Netherlands (8)
Anandi Sheth, MD (2) · Angela DM Kashuba, PharmD (2) · David Porter, MD (2) · Graeme Moyle (2) · Kristine B Patterson, MD (2) · Mark Mirochnick, MD (2) · Martin Markowitz, MD (2) · A IM Hoepelman, MD, PhD (1) · Alan Winston (1) · Alan Winston, MB BH (1) · Alan Winston, MBChB (1) · Alan Winston, MD (1)
PMID 18832244, PMID 18832245, PMID 20703158, PMID 24419064, PMID 30192390, PMID 34343443, PMID 16470119, PMID 16988514, PMID 18366444, PMID 18795962, PMID 18989231, PMID 19432546, PMID 20002783, PMID 20151839, PMID 20632458, PMID 20949133, PMID 21283017, PMID 21388938, PMID 21436711, PMID 21502084, PMID 21987241, PMID 22083071, PMID 22129166, PMID 22174752, PMID 22251436, PMID 22740718, PMID 22784116, PMID 23046968, PMID 23305215, PMID 23354282, PMID 23364475, PMID 23392467, PMID 23589670, PMID 23596247, PMID 23731330, PMID 23797691, PMID 24244635, PMID 24352352, PMID 24535278, PMID 24623833, PMID 25162818, PMID 25227930, PMID 25261418, PMID 25320633, PMID 25407158, PMID 25701561, PMID 25923596, PMID 25950206, PMID 25959631, PMID 26060295
2008 (3), 2009 (3), U01AI068636 (2), 2014 (1), 2017 (1), K23AI077355 (1), KL2TR000455 (1), R01AI122319 (1), R01MH058076 (1), U01AI068632 (1), U01HL069294 (1)